Bảng 3.10. Tỷ lệ dương tính với ALK trong các nhóm chẩn đoán
Típ KQ Típ nang Típ đặc Típ vi nhú Típ nhú Típ biến thể Tổng (-) (+) Tổng Nhận xét:
CHƯƠNG 4 DỰ KIẾN BÀN LUẬN
- Tỷ lệ các thứ típ mô học trong UTBMT
- Bàn luận về tỷ lệ bộc lộ của ALK (tỷ lệ âm tính, dương tính)
- Bàn luận về mối liên quan giữa tỷ lệ dương tính với đặc điểm tuổi, giới, hút thuốc
DỰ KIẾN KẾT LUẬN
- KLvề tỷ lệ các thứ típ mô học
KẾ HOẠCH NGHIÊN CỨU
Thời gian Tên công việc
Tháng 5-6/2019 - Hoàn thành và nộp đề cương
Tháng 7/ 2019 - Báo cáo thông qua đề cương theo lịch của Bộ môn - Hoàn thiện đề cương nộp phòng Đào tạo – Sau đại học Tháng 8/2019
6/2020
- Thu thập số liệu theo bệnh án nghiên cứu - Thực hiện các kĩ thuật trong nghiên cứu - Nhập số liệu vào phần mềm phân tích số liệu Tháng 6 - 8/2020 - Xử lý và phân tích số liệu - Viết bàn luận Tháng 8 -10/2020
- Hoàn thiện đề tài
- Báo cáo kết quả theo lịch của phòng Đào tạo Sau đại học
1. Siegel R.L, Miller K.D and Jemal A (2016), Cancer statistics. CA: A
Cancer Journal for Clinicians, 66, 7-30.
2. Yamaguchi T, Yanagisawa K, Sugiyama R et al (2012), NKX2- 1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer cell, 21, 348-361.
3. Hirsch FR, Sequist LV, Gore I, Mooradian M, et al (2017). Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP). Cancer; 124(11):2407-2414.
4. Iwahara T, et al (1997). Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system.
Oncogene;14(4):439-449
5. Ardini E, et al (2010). Cancer Lett.299:81-94 6. Grande et al (2011). Mol Cancer Ther; 10:569-579
7. Murry W. Wynes, Lynette M. Sholl, Manfred Dietel, Ed Schuuring, Ming S. Tsao, et al (2014). An International Interpretation Study using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance Between ALK IHC and ALK FISH and Between Evaluators. Journal Thoracic Oncology ; 9(5): 631–638.
8. Maximilian von Laffertet.al. (2014). Multicenter Immunohistochemical ALK-Testing of Non-Small Cell Lung Cancer Shows High Concordance after Harmonization of Techniques and Interpretation Criteria. Journal of
Thoracic Oncology, Volume 9, Number 11.
9. Kentaro Inamura, MD, PhD, Kengo Takeuchi, MD, PhD et al (2008): EML4-ALK Fusion Is Linked to Histological Characteristic in a Subset of Lung Cancers, Journal of Thoraccic Oncology Volume 3, Number 1.
TTF-1 cell lineage, an acinar histology, and young set. Modern
Pathology 22, 508-515.
11. Scott J, Mari Mino – Kenudson et al (2009). Unique Clinicopathologic Features Characterize ALK – Rearranged Lung Adenocarcinoma in the Western Population. Clin Cancer Res 2009; 15(16) August 15.
12. Akihiko Yoshida, MD. Koji Tsuta, MD, PhD et al (2011). Comprehensive Histologic Analysis of ALK –Rearranged Lung Carcinomas. Am J Surg
Patho. Volume 35, Number 8, August.
13. Michiya Nishino, Veronica E klepeis et al (2012). Histogic and cytomorphologic features of ALK-rearranged lung adenocarcinomas.
Modern Pathology 25, 1462-1472.
14. Hyojin Kim, Se Jin Jang et al (2013). Acomprehensive Comparative Analysis of the Histomorphological Features of ALK –Rearrangeg Lung Adenocarcinoma Based on Driver Oncogene Mutations: Frequent Expression of Epithelial –Mesenchymal Transition Markers than Other Genotype. October 2013 / Volume 8 /Issue 10/e76999
15. Akihiko Yoshida, MD. Koji Tsuta, MD, PhD et al(2011). Frequent ALK –rearranged and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component. Lung cancer 72; 309-315
16. Cristina Teixido, Niki Karachaliou et al (2018). Concodance of IHC, FISH and RT-PCR for EML4-ALK rearrangements. Review Article 15 May 2018/page 14/2017 Roche
17. Anne McLeer – Florin, PhD, Denis Moro – Sibilot, MD et al (2018). Dual IHC and FISH testing for ALK Gene Rearrangements in lung adenocarinomas in a Routine Practice. Review Article 15 May 2018/page 14/2017 Roche
cancer. Nature. 448:561–566.
19. Rikova K, Guo A, Zeng Q, et al (2007). Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 131:1190–1203.
20. Alice T. Shaw and Jeffrey A. Engelman (2013). ALK in Lung Cancer: Past, Present, and Future. J Clin Oncol. 10; 31(8): 1105–1111.
21. Morris SW, Kirstein MN, Valentine MB, et al (1994). Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's
lymphoma. Science. 263:1281–1284.
22. Lawrence B, Perez-Atayde A, Hibbard MK, et al (2000). TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am
J Pathol. 157:377–384.
23. Hernández L, Pinyol M, Hernández S, et al (1999). TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK
translocations.Blood.94:3265–3268.
24. Takeuchi K, Choi YL, Togashi Y, et al (2009). KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer
Res.15:3143–3149.
25. Togashi Y, Soda M, Sakata S, et al (2012). KLC1-ALK: A novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One. 7:e31323.
26. Chiarle R, Voena C, Ambrogio C, et al (2008). The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 8:11–23.
28. Chen Z, Sasaki T, Tan X, et al (2010). Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res;70:9827–9836.
29. McDermott U, Iafrate AJ, Gray NS, et al (2008). Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res. 68:3389–3395.
30. Shaw AT, Yeap BY, Mino-Kenudson M, et al (2009). Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 27:4247–4253.
31. Wong DW, Leung EL, So KK, et al (2009). The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 115:1723–1733.
32. Kwak EL, Bang YJ, Camidge DR, et al (2010). Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med.363:1693– 1703.
33. Cui JJ, Tran-Dubé M, Shen H, et al (2011). Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem.54:6342–6363.
34. Camidge DR, Bang YJ, Kwak EL, et al (2011). Progression-free survival (PFS) from a phase 1 study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J Clin
Oncol.29(suppl):65s. abstr 2501.
35. Hanna N, Shepherd FA, Fossella FV, et al. (2004). Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.J Clin Oncol. 22:1589– 1597.
37. Kim D-W, Ahn M-J, Shi Y, et al (2012). Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer. J Clin Oncol. 30(suppl):488s. abstr 7533.
38. Lindeman NI, Cagle PT, Beasley MB, et al (2013). Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn. 15:415–53.
39. Lira ME, Kim TM, Huang D, et al (2013). Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer. J
Mol Diagn. 15:51–61.
40. http://www.abbott.com/news-media/press-releases/2011-aug26.htm
41. Wu YC, Chang IC, Wang CL, et al (2013). Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non- small cell lung cancer patients in Taiwan. PLoS One. 2013;8:e70839. 42. Li Y, Pan Y, Wang R, Sun Y, et al (2013). ALK-rearranged lung cancer in
Chinese: a comprehensive assessment of clinicopathology, IHC, FISH and RT-PCR. PLoS One. 8:e69016.
43. Lamant L, Meggetto F, al Saati T, et al (1996). High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining. Blood. 87:284–91.
44. Pulford K, Lamant L, Morris SW, et al (1997). Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)- ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood. 89:1394–04.
lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res. 16:1561–71.
46. Thunnissen E, Bubendorf L, Dietel M, et al (2012). EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations.Virchows Arch. 461:245–57.
47. Robertson FM, Petricoin Iii EF, Van Laere SJ, et al (2013). Presence of anaplastic lymphoma kinase in inflammatory breast
cancer.Springerplus.2:497.
48. Sukov WR, Hodge JC, Lohse CM, et al (2012). ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcomein a large series of consecutively treated patients. Mod
Pathol.25:1516–25.
49. Thunnissen E, Bubendorf L, Dietel M, et al (2012). EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch. 461:245–57.
50. Paik JH, Choe G, Kim H, Choe JY, et al (2011). Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J
Thorac Oncol. 6:466–72.
51. Zhang YG, Jin ML, Li L, et al (2013). Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, immunohistochemistry, and real-time quantitative RT- PCR on paraffin-embedded tissues. PLoS
One. 2013;8:e64821.
52. Wang R, Pan Y, Li C, Hu H, et al (2012). The use of quantitative real- time reverse transcriptase PCR for 5' and 3' portions of ALK transcripts to detect ALK rearrangements in lung cancers. Clin Cancer Res.18:4725–32.
ALK. J Clin Oncol. 27:4247–53.
54. Geiss GK, Bumgarner RE, Birditt B, et al (2008). Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat
Biotechnol. 26:317–25.
55. Pulford K, Lamant L, Espinos E, et al (2004). The emerging normal and disease-related roles of anaplastic lymphoma kinase. Cell Mol Life Sci. 61:2939–53.
56. Ren H, Tan ZP, Zhu X, et al (2012). Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer. Cancer
Res. 72:3312–23.
57. Peled N, Palmer G, Hirsch FR, et al (2012). Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib- sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. J Thorac Oncol. 7:e14–6.
58. Lin E, Li L, Guan Y, Soriano R, et al (2009). Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res. 7:1466–76.
59. Rodney E. Shackelford, Moiz Vora,Kim Mayhall, and James Cotelingam (2014). ALK-rearrangements and testing methods in non-small cell lung cancer: a review. Genes Cancer. 5(1-2): 1–14. 60. Eunhee S. Yi, MD, Jennifer M. Boland, MD et al. Correlation of IHC
and FISH for ALK Gene Rearrangements in Non-small Cell Lung Carcinoma in a Routine Practice.
press, Lion
62. Dimitra Repana and James Spicer (2017). Epidemiology of Lung Cancer, In Springer International Publishing Switzerland 2017 M. Loda et al. (eds.), Pathology and Epidemiology of Cancer, DOI 10.1007/978- 3-319-35153-7_19; 347- 416.
Mã bệnh án:………..Mã Phiếu:……… 1. Họ tên:………1.1.Tuổi…...1.2. Giới: (1)Nam (2)Nữ 1.3. Địa chỉ: (1)Nông thôn (2) Thành thị (3) Miền núi (4) Khác………… 1.4. Ngày vào viện:………..………..
2. Chẩn đoán mô bệnh học phân loại ung thư biểu mô tuyến:
... 3. Độ mô học: ... 3. Giai đoạn bệnh: ... 4. Chẩn đoán HMMD (nếu có): - CK7: (1) Dương tính (+/++/+++), (2) Âm tính - TTF1: (1) Dương tính (+/++/+++), (2) Âm tính - Napsin A: (1) Dương tính (+/++/+++), (2) Âm tính
- Các dấu ấn khác (nếu cần):...
6. Kết quả bộc lộ ALK: Dương tính/ Âm tính
% tế bào u bộc lộ (TPS): ...
6.Mã bệnh phẩm:………... 7. Ghi chú:………....